Zhejiang China Commodities City Group Co.Ltd(600415) pre increase of net profit by 30% – 50% in 2021
Zhejiang China Commodities City Group Co.Ltd(600415) release performance forecast. It is estimated that the net profit attributable to the shareholders of the listed company in 2021 will increase by 278 million yuan to 464 million yuan, a year-on-year increase of 30% to 50%.
During the reporting period, the company took the chinagoods platform as the core and formed a digital trade service system with “trade data as the core, credit rating as the basis and one-stop performance as the characteristics”. The gmv16.8 billion yuan of the chinagoods platform achieved double growth in revenue and profit. The business model of some new business lines of the company has gradually matured, the performance has improved, and the investment income of joint (joint) companies has increased significantly.
Shuangliang Eco-Energy Systems Co.Ltd(600481) the application for non-public offering of shares was approved
Shuangliang Eco-Energy Systems Co.Ltd(600481) announcement: on January 10, 2022, the development and Examination Commission of China Securities Regulatory Commission examined the company’s application for non-public offering of shares. According to the audit results, the company’s application for non-public offering of shares was approved.
Jiangsu Hengrui Medicine Co.Ltd(600276) obtained the drug registration certificate
Jiangsu Hengrui Medicine Co.Ltd(600276) announcement: the company has received the drug registration certificate approved and issued by the State Food and drug administration. Proline hengglijing tablets obtained the drug registration certificate. The approved indication is “this product is suitable for improving glycemic control in adults with type 2 diabetes; the drug registration certificate is obtained from Dulcie’s tablets of hydroxyethane sulfonate”. The approved indication is “this product combined with fluticasone in the treatment of recurrent or metastatic breast cancer with hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative after endocrine therapy.” Darcilide hydroxyethanesulfonate is a new class 1 Chemical drug independently developed by Jiangsu Hengrui Medicine Co.Ltd(600276) . It is an oral, efficient and selective small molecule CDK4 / 6 inhibitor.
The registration certificate of Shandong Pharmaceutical Co., Ltd. issued by Shandong Pharmaceutical Administration was received on the same day. Ambroxol hydrochloride oral liquid obtained the drug registration certificate. The drug can increase the secretion of serous glands of respiratory mucosa and reduce the secretion of mucus glands, so as to reduce the viscosity of sputum, promote the secretion of pulmonary surfactant, increase the movement of bronchial cilia, and make sputum easy to cough up. It is suitable for viscous sputum and difficult expectoration caused by acute and chronic bronchitis.
Beijing Tiantan Biological Products Corporation Limited(600161) performance express: net profit in 2021 increased by nearly 20% year-on-year
Beijing Tiantan Biological Products Corporation Limited(600161) release performance express. In 2021, the total revenue was 410861100 yuan, a year-on-year increase of 19.24%; The net profit attributable to the shareholders of the listed company was 763.8146 million yuan, a year-on-year increase of 19.53%. The basic earnings per share is 0.57 yuan.
Jiangsu Hengrui Medicine Co.Ltd(600276) obtained the drug registration certificate
Jiangsu Hengrui Medicine Co.Ltd(600276) announcement: the company has received the drug registration certificate approved and issued by the State Food and drug administration. Proline hengglijing tablets obtained the drug registration certificate. The approved indication is “this product is suitable for improving glycemic control in adults with type 2 diabetes; the drug registration certificate is obtained from Dulcie’s tablets of hydroxyethane sulfonate”. The approved indication is “this product combined with fluticasone in the treatment of recurrent or metastatic breast cancer with hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative after endocrine therapy.” Darcilide hydroxyethanesulfonate is a new class 1 Chemical drug independently developed by Jiangsu Hengrui Medicine Co.Ltd(600276) . It is an oral, efficient and selective small molecule CDK4 / 6 inhibitor.
The registration certificate of Shandong Pharmaceutical Co., Ltd. issued by Shandong Pharmaceutical Administration was received on the same day. Ambroxol hydrochloride oral liquid obtained the drug registration certificate. The drug can increase the secretion of serous glands of respiratory mucosa and reduce the secretion of mucus glands, so as to reduce the viscosity of sputum, promote the secretion of pulmonary surfactant, increase the movement of bronchial cilia, and make sputum easy to cough up. It is suitable for viscous sputum and difficult expectoration caused by acute and chronic bronchitis.
Sinosoft Co.Ltd(603927) shareholders plan to reduce their holdings of no more than 2% of the company’s shares
According to the announcement of Sinosoft Co.Ltd(603927) , Guo Dan, a shareholder with a shareholding of 3.7547%, plans to reduce the company’s shares by means of centralized bidding transaction, with a total of no more than 11872000 shares, accounting for 2% of the total number of Sinosoft Co.Ltd(603927) shares at present.
China Jushi Co.Ltd(600176) net profit in 2021 is expected to increase by 140% – 190%
China Jushi Co.Ltd(600176) release performance forecast. It is estimated that the net profit attributable to the shareholders of the listed company in 2021 will increase by 3382.56 million yuan – 4590.61 million yuan, a year-on-year increase of 140% – 190%. In 2021, there will be strong demand in the downstream application field of glass fiber, the volume and price of roving products of the company will rise simultaneously, the export sales volume will increase significantly, and the sales price of electronic cloth will increase significantly.
Hangzhou Youngsun Intelligent Equipment Co.Ltd(603901) net profit in 2021 increased by 41% – 64%
Hangzhou Youngsun Intelligent Equipment Co.Ltd(603901) release performance forecast. It is estimated that the net profit attributable to the shareholders of the listed company in 2021 will be 24 million yuan to 280 million yuan, with a year-on-year increase of 40.66% to 64.10%.
During the reporting period, the growth in the demand for packaging equipment in dairy, alcohol and leisure food industries, which account for a large proportion of the downstream industries of the company’s products, and the product competitive advantage brought by the transformation of the company’s continuous R & D investment results jointly promoted the high growth of the company’s overall revenue scale.
Wuxi Acryl Technology Co.Ltd(603722) net profit in 2021 increased by 66% – 101%
Wuxi Acryl Technology Co.Ltd(603722) release performance forecast. It is estimated that the net profit attributable to shareholders of listed companies will be 86 million yuan to 104 million yuan in 2021, with a year-on-year increase of 66.09% to 100.86%.
In 2021, the wind power is in a rush state. As one of the molding materials of wind power blades, the demand for polyether amine maintains a high growth; Global crude oil prices continued to rise and shale oil and gas production increased, resulting in a sharp increase in the demand for polyether amine in the international market. Therefore, limited by polyether amine production capacity, the price of polyether amine products has been rising steadily throughout the year. Although the price of raw materials fluctuated throughout the year, the overall profitability of polyether amine has been growing steadily.
(source: Shanghai Securities News · China Securities Network)
